

Europe Pharma ADMET Testing Market Forecast to 2028 - COVID-19 Impact and Regional Analysis - by Testing Type (In Vivo ADMET Testing, In Vitro ADMET Testing, and In Silico ADMET Testing), Technology (Cell Culture, High Throughput, Molecular Imaging, and OMICS Technology), and Application (Systemic Toxicity, Renal Toxicity, Hepatotoxicity, Neurotoxicity, and Others)

Market Report | 2022-10-07 | 142 pages | The Insight Partners

AVAILABLE LICENSES:

- Single User Price \$3000.00
- Site Price \$4000.00
- Enterprise Price \$5000.00

Report description:

The pharma ADMET testing market in Europe is expected to grow from US\$ 2,199.98 million in 2022 to US\$ 3,971.68 million by 2028. It is estimated to grow at a CAGR of 10.3% from 2022 to 2028.

Companies in the pharmaceuticals and biotechnology industries focus on the expansion of their research & development capabilities and drug manufacturing capacity. Rapid developments in computational software and the introduction of novel field technologies are estimated to raise the efficiency of drug development during the forecast period. For instance, toxicity, cytochrome p450 induction, and in vitro metabolism assays, among others, are being incorporated into a single assay on liver hepatocytes. Similarly, 3D cell culture models with multiple tissue cell types are emerging as promising systems.

Moreover, microfluidic organ-on-a-chip approaches, such as those commercialized by Emulate, are becoming more mainstream for predictive ADMET studies. ADMET Predictor by Simulations Plus, Inc., ADME/Tox by Sigma-Aldrich, LLC., PhysChem and ADME-Tox Prediction by ACD/Labs, PK/PD Database for Pharmacokinetic Properties by the Laboratory of Computational and Medicinal Chemistry, etc., are several tools developed for predicting toxicity related to ADME. Artificial intelligence (AI) may be used to simulate the ADME of drugs, determine if a therapeutic molecule will be effective in humans, and predict safety concerns.

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

During the period of post-COVID recovery, the current popularity and concurrent emergence of AI and machine learning (ML) are likely to have a substantial impact on drug design and development. These technologies have decreased the need for human intervention and raised the quality of life of people as they can be implemented in designing superior-quality healthcare goods. With the help of specialized molecular modeling techniques, such as in-silico simulation, pharmacophore modeling, molecular dynamics, virtual screening, and molecular docking, AI&ML-driven rational drug design seeks to explain the unforeseen bioactivity of natural products most perfectly in a limited timeframe.

Additionally, it describes the molecular interaction of drugs and their targets to create more effective drug leads. In January 2022, Charles River Laboratories and Valo Health, LLC, a technology firm leveraging human-centric data and AI-based computing, established a multi-year strategic collaboration to change the drug research & development process. A new revolutionary, AI-enabled drug discovery and development platform will be made available through this partnership by using Charles River's discovery optimization capabilities, including medicinal chemistry, ADME, biology, and pharmacology, and Valo's Opal Platform for small molecule development, which utilizes a "closed-loop" in a silico-experimental platform that rapidly iterates using program data to identify novel compounds. Thus, ADME testing based on automation, AI, and ML, among other technologies, is becoming an important part of the digital health boom, providing significant growth opportunities for the Pharma ADMET testing market.

Europe Pharma ADMET Testing Market Revenue and Forecast to 2028 (US\$ Million)

Europe Pharma ADMET Testing Market Segmentation

The Europe pharma ADMET testing market is segmented by testing type, technology, application, and country. Based on testing type, the market is segmented into in vivo ADMET testing, in vitro ADMET testing, and in silico ADMET testing. The in vivo ADMET testing segment is dominating the market in 2022. Based on technology, the market is segmented into cell culture, high throughput, molecular imaging, and OMICS technology. The cell culture segment is dominating the market in 2022. Based on application, the market is segmented into systemic toxicity, renal toxicity, hepatotoxicity, neurotoxicity, and others. The systemic toxicity segment is dominating the market in 2022. Based on country, the market is segmented into Germany, the UK, France, Italy, Spain, and the Rest of Europe. Further, the Rest of Europe dominated the market in 2022.

A few key players dominating the Europe pharma ADMET testing market are Agilent Technologies, Inc.; Bio-Rad Laboratories, Inc.; Biovia (Dassault Systemes); Charles River Laboratories; CMIC HOLDINGS Co., LTD; Cyprotex Limited; IQVIA Inc.; MERCK KGaA; Promega Corporation; and Wuxi AppTec.

Table of Contents:

TABLE OF CONTENTS

1. Introduction
 - 1.1 Scope of the Study
 - 1.2 The Insight Partners Research Report Guidance
 - 1.3 Market Segmentation
 - 1.3.1 Europe Pharma ADMET Testing Market - By Testing Type
 - 1.3.2 Europe Pharma ADMET Testing Market - By Technology
 - 1.3.3 Europe Pharma ADMET Testing Market - By Application
 - 1.3.4 Europe Pharma ADMET Testing Market - By Country
2. Europe Pharma ADMET Testing Market- Key Takeaways
3. Research Methodology
 - 3.1 Coverage
 - 3.2 Secondary Research

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 3.3 Primary Research
- 4. Europe Pharma ADMET Testing Market - Market Landscape
 - 4.1 Overview
 - 4.2 PEST Analysis
 - 4.2.1 Europe - PEST Analysis
 - 4.3 Expert Opinion
- 5. Europe Pharma ADMET Testing Market - Key Market Dynamics
 - 5.1 Market Drivers
 - 5.1.1 High Rate of Late-Stage Drug Failure
 - 5.1.2 Rising Number of Product Approvals and Launches
 - 5.2 Market Restraints
 - 5.2.1 High Cost of ADME Testing Studies
 - 5.3 Market Opportunities
 - 5.3.1 Automation and Advancements in ADME Testing
 - 5.4 Future Trends
 - 5.4.1 The Advent of High-Throughput Screening
 - 5.5 Impact Analysis
- 6. Pharma ADMET Testing Market- Europe Analysis
 - 6.1 Europe Pharma ADMET Testing Market Revenue Forecast and Analysis
- 7. Europe Pharma ADMET Testing Market- By Testing Type
 - 7.1 Overview
 - 7.2 Europe Pharma ADMET Testing Market, By Testing Type 2022 & 2028 (%)
 - 7.3 In Vivo ADMET Testing
 - 7.3.1 Overview
 - 7.3.2 In Vivo ADMET Testing - Revenue and Forecast to 2028 (US\$ Million)
 - 7.4 In Vitro ADMET Testing
 - 7.4.1 Overview
 - 7.4.2 In Vitro ADMET Testing - Revenue and Forecast to 2028 (US\$ Million)
 - 7.5 In Silico ADMET Testing
 - 7.5.1 Overview
 - 7.5.2 In Silico ADMET Testing - Revenue and Forecast to 2028 (US\$ Million)
- 8. Europe Pharma ADMET Testing Market- By Technology
 - 8.1 Overview
 - 8.2 Europe Pharma ADMET Testing Market, By Technology 2022 & 2028 (%)
 - 8.3 Cell Culture
 - 8.3.1 Overview
 - 8.3.2 Cell Culture - Market Revenue and Forecast to 2028 (US\$ Million)
 - 8.4 High Throughput
 - 8.4.1 Overview
 - 8.4.2 High Throughput - Market Revenue and Forecast to 2028 (US\$ Million)
 - 8.5 Molecular Imaging
 - 8.5.1 Overview
 - 8.5.2 Molecular Imaging - Market Revenue and Forecast to 2028 (US\$ Million)
 - 8.6 OMICS Technology
 - 8.6.1 Overview
 - 8.6.2 OMICS Technology - Market Revenue and Forecast to 2028 (US\$ Million)
- 9. Europe Pharma ADMET Testing Market- By Application

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 9.1 Overview
- 9.2 Europe Pharma ADMET Testing Market, By Application 2022 & 2028 (%)
- 9.3 Systemic Toxicity
 - 9.3.1 Overview
 - 9.3.2 Systemic Toxicity - Market Revenue and Forecasts to 2028 (US\$ Million)
- 9.4 Renal Toxicity
 - 9.4.1 Overview
 - 9.4.2 Renal Toxicity - Market Revenue and Forecasts to 2028 (US\$ Million)
- 9.5 Hepatotoxicity
 - 9.5.1 Overview
 - 9.5.2 Hepatotoxicity - Market Revenue and Forecasts to 2028 (US\$ Million)
- 9.6 Neurotoxicity
 - 9.6.1 Overview
 - 9.6.2 Neurotoxicity - Market Revenue and Forecasts to 2028 (US\$ Million)
- 9.7 Others
 - 9.7.1 Overview
 - 9.7.2 Others - Revenue and Forecasts to 2028 (US\$ Million)
- 10. Europe Pharma ADMET Testing Market- Country Analysis
 - 10.1 Europe: Pharma ADMET Testing Market
 - 10.1.1 Overview
 - 10.1.2 Europe: Pharma ADMET Testing Market, by Country, 2022 & 2028 (%)
 - 10.1.2.1 Germany: Pharma ADMET Testing Market - Revenue and Forecast to 2028 (US\$ Million)
 - 10.1.2.1.1 Germany: Pharma ADMET Testing Market - Revenue and Forecast to 2028 (US\$ Million)
 - 10.1.2.1.2 Germany: Pharma ADMET Testing Market, by Testing Type - Revenue and Forecast to 2028 (US\$ Million)
 - 10.1.2.1.3 Germany: Pharma ADMET Testing Market, by Technology- Revenue and Forecast to 2028 (US\$ Million)
 - 10.1.2.1.4 Germany: Pharma ADMET Testing Market, by Application - Revenue and Forecast to 2028 (US\$ Million)
 - 10.1.2.2 UK: Pharma ADMET Testing Market - Revenue and Forecast to 2028 (US\$ Million)
 - 10.1.2.2.1 UK: Pharma ADMET Testing Market - Revenue and Forecast to 2028 (US\$ Million)
 - 10.1.2.2.2 UK: Pharma ADMET Testing Market, by Testing Type - Revenue and Forecast to 2028 (US\$ Million)
 - 10.1.2.2.3 UK: Pharma ADMET Testing Market, by Technology- Revenue and Forecast to 2028 (US\$ Million)
 - 10.1.2.2.4 UK: Pharma ADMET Testing Market, by Application - Revenue and Forecast to 2028 (US\$ Million)
 - 10.1.2.3 France: Pharma ADMET Testing Market - Revenue and Forecast to 2028 (US\$ Million)
 - 10.1.2.3.1 France: Pharma ADMET Testing Market - Revenue and Forecast to 2028 (US\$ Million)
 - 10.1.2.3.2 France: Pharma ADMET Testing Market, by Testing Type - Revenue and Forecast to 2028 (US\$ Million)
 - 10.1.2.3.3 France: Pharma ADMET Testing Market, by Technology- Revenue and Forecast to 2028 (US\$ Million)
 - 10.1.2.3.4 France: Pharma ADMET Testing Market, by Application - Revenue and Forecast to 2028 (US\$ Million)
 - 10.1.2.4 Italy: Pharma ADMET Testing Market - Revenue and Forecast to 2028 (US\$ Million)
 - 10.1.2.4.1 Italy: Pharma ADMET Testing Market - Revenue and Forecast to 2028 (US\$ Million)
 - 10.1.2.4.2 Italy: Pharma ADMET Testing Market, by Testing Type - Revenue and Forecast to 2028 (US\$ Million)
 - 10.1.2.4.3 Italy: Pharma ADMET Testing Market, by Technology- Revenue and Forecast to 2028 (US\$ Million)
 - 10.1.2.4.4 Italy: Pharma ADMET Testing Market, by Application - Revenue and Forecast to 2028 (US\$ Million)
 - 10.1.2.5 Spain: Pharma ADMET Testing Market - Revenue and Forecast to 2028 (US\$ Million)
 - 10.1.2.5.1 Spain: Pharma ADMET Testing Market - Revenue and Forecast to 2028 (US\$ Million)
 - 10.1.2.5.2 Spain: Pharma ADMET Testing Market, by Testing Type - Revenue and Forecast to 2028 (US\$ Million)
 - 10.1.2.5.3 Spain: Pharma ADMET Testing Market, by Technology- Revenue and Forecast to 2028 (US\$ Million)
 - 10.1.2.5.4 Spain: Pharma ADMET Testing Market, by Application - Revenue and Forecast to 2028 (US\$ Million)
 - 10.1.2.6 Rest of Europe: Pharma ADMET Testing Market - Revenue and Forecast to 2028 (US\$ Million)

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 10.1.2.6.1 Rest of Europe: Pharma ADMET Testing Market - Revenue and Forecast to 2028 (US\$ Million)
- 10.1.2.6.2 Rest of Europe: Pharma ADMET Testing Market, by Testing Type - Revenue and Forecast to 2028 (US\$ Million)
- 10.1.2.6.3 Rest of Europe: Pharma ADMET Testing Market, by Technology- Revenue and Forecast to 2028 (US\$ Million)
- 10.1.2.6.4 Rest of Europe: Pharma ADMET Testing Market, by Application - Revenue and Forecast to 2028 (US\$ Million)
- 11. Europe Pharma ADMET Testing Market-Industry Landscape
 - 11.1 Overview
 - 11.2 Organic Developments
 - 11.2.1 Overview
 - 11.3 Inorganic Developments
 - 11.3.1 Overview
- 12. Company Profiles
 - 12.1 CMIC HOLDINGS Co., LTD
 - 12.1.1 Key Facts
 - 12.1.2 Business Description
 - 12.1.3 Products and Services
 - 12.1.4 Financial Overview
 - 12.1.5 SWOT Analysis
 - 12.1.6 Key Developments
 - 12.2 Charles River Laboratories
 - 12.2.1 Key Facts
 - 12.2.2 Business Description
 - 12.2.3 Products and Services
 - 12.2.4 Financial Overview
 - 12.2.5 SWOT Analysis
 - 12.2.6 Key Developments
 - 12.3 WuXi AppTec
 - 12.3.1 Key Facts
 - 12.3.2 Business Description
 - 12.3.3 Products and Services
 - 12.3.4 Financial Overview
 - 12.3.5 SWOT Analysis
 - 12.3.6 Key Developments
 - 12.4 Promega Corporation
 - 12.4.1 Key Facts
 - 12.4.2 Business Description
 - 12.4.3 Products and Services
 - 12.4.4 Financial Overview
 - 12.4.5 SWOT Analysis
 - 12.4.6 Key Developments
 - 12.5 Sigma-Aldrich (MERCK KGaA)
 - 12.5.1 Key Facts
 - 12.5.2 Business Description
 - 12.5.3 Products and Services
 - 12.5.4 Financial Overview
 - 12.5.5 SWOT Analysis
 - 12.5.6 Key Developments
 - 12.6 Agilent Technologies, Inc.

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 12.6.1 Key Facts
- 12.6.2 Business Description
- 12.6.3 Products and Services
- 12.6.4 Financial Overview
- 12.6.5 SWOT Analysis
- 12.6.6 Key Developments
- 12.7 Biovia (Dassault Systemes)
- 12.7.1 Key Facts
- 12.7.2 Business Description
- 12.7.3 Products and Services
- 12.7.4 Financial Overview
- 12.7.5 SWOT Analysis
- 12.7.6 Key Developments
- 12.8 Cypotex Limited
- 12.8.1 Key Facts
- 12.8.2 Business Description
- 12.8.3 Products and Services
- 12.8.4 Financial Overview
- 12.8.5 SWOT Analysis
- 12.8.6 Key Developments
- 12.9 Bio-Rad Laboratories, Inc.
- 12.9.1 Key Facts
- 12.9.2 Business Description
- 12.9.3 Products and Services
- 12.9.4 Financial Overview
- 12.9.5 SWOT Analysis
- 12.9.6 Key Developments
- 12.10 IQVIA Inc.
- 12.10.1 Key Facts
- 12.10.2 Business Description
- 12.10.3 Products and Services
- 12.10.4 Financial Overview
- 12.10.5 SWOT Analysis
- 12.10.6 Key Developments
- 13. Appendix
- 13.1 About The Insight Partners
- 13.2 Glossary of Terms

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Europe Pharma ADMET Testing Market Forecast to 2028 - COVID-19 Impact and Regional Analysis - by Testing Type (In Vivo ADMET Testing, In Vitro ADMET Testing, and In Silico ADMET Testing), Technology (Cell Culture, High Throughput, Molecular Imaging, and OMICS Technology), and Application (Systemic Toxicity, Renal Toxicity, Hepatotoxicity, Neurotoxicity, and Others)

Market Report | 2022-10-07 | 142 pages | The Insight Partners

To place an Order with Scotts International:

- ☐ - Print this form
- ☐ - Complete the relevant blank fields and sign
- ☐ - Send as a scanned email to support@scotts-international.com

ORDER FORM:

Select license	License	Price
	Single User Price	\$3000.00
	Site Price	\$4000.00
	Enterprise Price	\$5000.00
		VAT
		Total

*Please circle the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 346.

** VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	<input type="text"/>	Phone*	<input type="text"/>
First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>		
Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Address*	<input type="text"/>	City*	<input type="text"/>
Zip Code*	<input type="text"/>	Country*	<input type="text"/>
		Date	<input type="text" value="2025-05-13"/>
		Signature	<input type="text"/>